Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scans may spot gout risk years before first attack

NCT ID NCT05434858

Knowledge-focused Sponsor: Lille Catholic University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 21 people with high uric acid but no gout symptoms for up to 5 years. Researchers use ultrasound and CT scans to look for tiny crystal deposits in joints. The goal is to see if these deposits can predict who will later develop painful gout flares.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify who will develop gout before symptoms start, allowing earlier prevention.
What could go wrong
This is a very small observational study (21 people) with no treatment being tested. Results may not apply to everyone and cannot guarantee prediction accuracy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21 people

The number who actually took part.

Started

Sep 2022

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Serum urate level ≥ 80 mg/L on inclusion, * No current or previous clinical symptoms of gout (including clinically apparent flares or tophus), * Between 18 and 80 years old, * Able to give informed consent. Exclusion Criteria: * GFR (glomerular filtration rate) \<30 ml / min / 1.73 m² or dialysis, * Serious illness with a poor prognosis of less than 5 years, * Autoimmune inflammatory arthritis, * Change of geographical area within 5 years, * Previous analysis of synovial fluid showing crystals of MSU, * Presence of subcutaneous tophi, * Taking a hypouricaemic treatment (allopurinol, probenecid, benzbromarone, febuxostat, lesinurad), canakinumab, anakinra or colchicine, * Uricemia observed only after an acute decompensation of comorbidity * Pregnant or breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperuricemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperuricemia gout prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperuricemia

Contacts and locations

Locations

  • Lille Catholic Hospital

    Lille, Hauts-de-France, 59462, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.